SPOTLIGHT: Levaquin approval expanded

SPOTLIGHT ON... Levaquin approval expanded
Johnson & Johnson's short-course antibiotic Levaquin got the FDA's approval as a treatment for stubborn urinary-tract infections and kidney infection. Release

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.